Drug Database
Back to search

United States· US:50242-177_cc3e8671-e1bd-494e-bedb-de8dc0e2f482

Lunsumio Velo

A mosunetuzumab product containing mosunetuzumab, registered in United States by Genentech, Inc.. The same ATC class is registered in 12 of our 19 countries.

ATC L01FX25

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedLunsumio VeloATCL01FX25REGISTER NO.US:50242-177_cc3e8671…PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about mosunetuzumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Mosunetuzumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FX25 (mosunetuzumab), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 7 of them publish a price we can compare per daily dose
Search mosunetuzumab products by name

Mosunetuzumab · ATC L01FX25

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
MOSUNETUZUMAB
Manufacturer
Genentech, Inc.
Country
United States (US)
ATC code
L01FX25
ATC class
Mosunetuzumab
Defined daily dose
1.8 mg, P
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    50242-177-01

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mosunetuzumab in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mosunetuzumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Lunsumio
  • Liechtenstein · Lunsumio
  • Norway · Lunsumio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c5195c83-f87f-4352-a3ea-321b7c556f4e
GET /v1/drugs/c5195c83-f87f-4352-a3ea-321b7c556f4e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "SUBCUTANEOUS",
  "source": "ndc",
  "strength": "5",
  "substance": "MOSUNETUZUMAB",
  "productndc": "50242-177",
  "dosage_form": "INJECTION",
  "dea_schedule": null,
  "strength_unit": "mg/.5mL",
  "application_number": "BLA761263",
  "marketing_category": "BLA"
}
API referenceMCP serverPlans

See everything about mosunetuzumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console